Abstract 78P
Background
TT-00434 is an irreversible, highly selective inhibitor of FGFR1, 2, and 3 with potent preclinical activity against tumors harboring FGFR aberrations. We present initial results from the first-in-human phase 1 study of TT-00434 orally administrated in patients (pts) with solid tumors.
Methods
This phase 1, multicenter, open-label, dose-escalation study enrolled pts with advanced solid tumors who had exhausted all available standard treatments. An accelerated titration design followed by a standard 3 + 3 scheme was used. Pts received a single daily dose of TT-00434 continuously for 28-day cycles. Key objectives included determining the recommended phase 2 dose (RP2D), safety, PK, pharmacodynamics (PD) and preliminary antitumor activity.
Results
As of 7 Aug 2023, 11 eligible pts received TT-00434 40 mg (n = 1), 80 mg (n = 6), and 160 mg (n = 4). One pt in 160 mg experienced Grade (G) 2 fatigue, vomiting and dizziness, resulting in dose interruption for 13 days (≥7 days) in Cycle 1 which was qualified as DLTs. The most frequently reported treatment-related adverse events included hyperphosphatemia (91%), fatigue (45%), hypercalcemia (36%), dry mouth (36%) and decreased appetite (36%). Two G3 events of fatigue and hyponatremia (each n=1) were observed. No G4 or G5 AEs were reported. The exposure (AUC and Cmax) was dose proportional from 80 to 160 mg. The maximum serum phosphate concentration as PD biomarker reached plateau (6.1∼8.9 mg/mL) at 80 mg. Stable diseases were observed in 2 pts with bladder cancer and endometrial cancer. One cholangiocarcinoma pt with FGFR alteration (FGFR2(17)-ARHGAP24(3) fusion) treated at 80 mg achieved partial response. The treatment lasts 203+ days and is still ongoing. Based on safety, efficacy and PK/PD assessments, the RP2D was determined as 80 mg QD.
Conclusions
This first-in-human study of TT-00434 showed a manageable and well-tolerated safety profile. The preliminary antitumor activity was observed in pt with FGFR2 altered cholangiocarcinoma. Further evaluation of the efficacy and safety of TT-00434 in solid tumors with FGFR1-3 alterations is encouraged.
Clinical trial identification
NCT04830501.
Editorial acknowledgement
Legal entity responsible for the study
TransThera Sciences (Nanjing), Inc.
Funding
TransThera Sciences (Nanjing), Inc.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract